Brind.

Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

2 reports, 2 independent Updated Sep 14
Gone quiet
Reports
2
Developments
9
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Novartis licensed pelacarsen from Ionis, while multiple firms advance Lp(a) treatments.1 source
  2. Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.Sub-event
  3. Amgen and Novartis have developed similar drugs aimed at treating heart conditions.Sub-event
  4. Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.Sub-event
  5. Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.Sub-event
  6. Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.Sub-event
  7. Mineralys Therapeutics presented its clinical trial results at the American Heart Association sessions in Baltimore.Sub-event
  8. Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.Sub-event
Show 1 earlier step
  1. Companies are developing advanced experimental drugs for heart disease, informed by AHA guidelines and clinical practice.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped